References
- Kusumi I, Boku S, Takahashi Y. Psychopharmacology of atypical antipsychotic drugs: from the receptor binding profile to neuroprotection and neurogenesis. Psychiatry Clin Neurosci. 2015;69(5):243–258.
- Meltzer HY. Serotonergic mechanisms as targets for existing and novel antipsychotics. Handb Exp Pharmacol. 2012;212:87–124.
- Zheng W, Cai D-B, Zhang Q-E, et al. Adjunctive ondansetron for schizophrenia: a systematic review and meta-analysis of randomized controlled trials. J Psychiatr Res. 2019;113:27–33.
- Khokhar JY, Henricks AM, Sullivan EDK, et al. Unique effects of clozapine: a pharmacological perspective. Adv Pharmacol. 2018;82:137–162.
- Stahl SM. Parkinson’s disease psychosis as a serotonin-dopamine imbalance syndrome. CNS Spectr. 2016;21:355–359.
- Burstein ES. Relevance of 5-HT2A receptor modulation of pyramidal cell excitability for dementia-related psychosis: implications for pharmacotherapy. CNS Drugs. 2021;35:727–741.
- Baltzersen OB, Meltzer HY, Frokjaer VG, et al. Identification of a serotonin 2A receptor subtype of schizophrenia spectrum disorders with pimavanserin: the sub-sero proof-of-concept trial protocol. Front Pharmacol. 2020;11:591.
- Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31–41.
- Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962.
- Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al., Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multiepisode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–951.
- Xu H, Zhuang X. Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review. Neuropsychiatr Dis Treat. 2019;15:2087–2099.
- Naber D, Lambert M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs. 2009;23(23):649–659.
- Corponi F, Fabbri C, Bitter I, et al., Novel antipsychotics specificity profile: a clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Eur Neuropsychopharmacol. 2019;29(9):971–985.
- Nasrallah HA, Cucchiaro JB, Mao Y, et al. Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies. CNS Spectr. 2015;20(2):140–147.
- Harvey PD, Siu CO, Hsu J, et al. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension. Eur Neuropsychopharmacol. 2013;23(11):1373–1382.
- Rognoni C, Bertolani A, Jommi C. Second-generation antipsychotic drugs for patients with schizophrenia: systematic literature review and meta-analysis of metabolic and cardiovascular side effects. Clin Drug Investig. 2021;41(4):303–319.
- Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs. 2004;18(4):251–267.
- Laszlovszky I, Kiss B, Barabássy Á, et al. Cognitive improving properties of cariprazine, a dopamine D3 receptor preferring partial agonist: overview of nonclinical and clinical data. Eur Psychiatry. 2019;56(Suppl):S238.
- Németh G, Laszlovszky I, Czobor P, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled tri al. Lancet. 2017;389(10074):1103–1113.
- Syed AB, Brašić JR. The role of lumateperone in the treatment of schizophrenia. Ther Adv Psychopharmacol. 2021;11:20451253211034019.
- Bousman CA, Bengesser SA, Aitchison KJ, et al. Review and consensus on pharmacogenomic testing in psychiatry. Pharmacopsychiatry. 2021;54(1):5–17.
- Frazer A, Blier P. A neuroscience-based nomenclature (NbN) for psychotropic agents. Int J Neuropsychopharmacol. 2016;12(19):yw066.
- Heffernan MLR, Herman LW, Brown S, et al. Ulotaront: a TAAR1 agonist for the treatment of schizophrenia. ACS Med Chem Lett. 2021;13(1):92–98.
- Foster DJ, Bryant ZK, Conn PJ. Targeting muscarinic receptors to treat schizophrenia. Behav Brain Res. 2021;405:113201.